Literature DB >> 18500254

Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles.

Wuping Li1, Aravind Asokan, Zhijian Wu, Terry Van Dyke, Nina DiPrimio, Jarrod S Johnson, Lakshmanan Govindaswamy, Mavis Agbandje-McKenna, Stefan Leichtle, D Eugene Redmond, Thomas J McCown, Kimberly B Petermann, Norman E Sharpless, Richard J Samulski.   

Abstract

We report a DNA shuffling-based approach for developing cell type-specific vectors through directed evolution. Capsid genomes of adeno-associated virus (AAV) serotypes 1-9 were randomly fragmented and reassembled using PCR to generate a chimeric capsid library. A single infectious clone (chimeric-1829) containing genome fragments from AAV1, 2, 8, and 9 was isolated from an integrin minus hamster melanoma cell line previously shown to have low permissiveness to AAV. Molecular modeling studies suggest that AAV2 contributes to surface loops at the icosahedral threefold axis of symmetry, while AAV1 and 9 contribute to two- and fivefold symmetry interactions, respectively. The C-terminal domain (AAV9) was identified as a critical structural determinant of melanoma tropism through rational mutagenesis. Chimeric-1829 utilizes heparan sulfate as a primary receptor and transduces melanoma cells more efficiently than all serotypes. Further, chimeric-1829 demonstrates altered tropism in rodent skeletal muscle, liver, and brain including nonhuman primates. We determined a unique immunological profile based on neutralizing antibody (NAb) titer and crossreactivity studies strongly supporting isolation of a synthetic laboratory-derived capsid variant. Application of this technology to alternative cell/tissue types using AAV or other viral capsid sequences is likely to yield a new class of biological nanoparticles as vectors for human gene transfer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18500254      PMCID: PMC2632803          DOI: 10.1038/mt.2008.100

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  48 in total

1.  Insertional mutagenesis of AAV2 capsid and the production of recombinant virus.

Authors:  J E Rabinowitz; W Xiao; R J Samulski
Journal:  Virology       Date:  1999-12-20       Impact factor: 3.616

2.  Analysis of shuffled gene libraries.

Authors:  John M Joern; Peter Meinhold; Frances H Arnold
Journal:  J Mol Biol       Date:  2002-02-22       Impact factor: 5.469

Review 3.  Unraveling hot spots in binding interfaces: progress and challenges.

Authors:  Warren L DeLano
Journal:  Curr Opin Struct Biol       Date:  2002-02       Impact factor: 6.809

4.  SWISS-MODEL: An automated protein homology-modeling server.

Authors:  Torsten Schwede; Jürgen Kopp; Nicolas Guex; Manuel C Peitsch
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

5.  Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.

Authors:  Joseph E Rabinowitz; Fabienne Rolling; Chengwen Li; Hervè Conrath; Weidong Xiao; Xiao Xiao; R Jude Samulski
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Marker rescue of adeno-associated virus (AAV) capsid mutants: a novel approach for chimeric AAV production.

Authors:  Dawn E Bowles; Joseph E Rabinowitz; R Jude Samulski
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

7.  Enhancing rAAV vector expression in the lung.

Authors:  Isabel Virella-Lowell; Benjamin Zusman; Kevin Foust; Scott Loiler; Thomas Conlon; Sihong Song; Kye A Chesnut; Thomas Ferkol; Terence R Flotte
Journal:  J Gene Med       Date:  2005-07       Impact factor: 4.565

8.  Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection.

Authors:  C E Wobus; B Hügle-Dörr; A Girod; G Petersen; M Hallek; J A Kleinschmidt
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding.

Authors:  Shaun R Opie; Kenneth H Warrington; Mavis Agbandje-McKenna; Sergei Zolotukhin; Nicholas Muzyczka
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

10.  Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands.

Authors:  Selvarangan Ponnazhagan; Gandham Mahendra; Sanjay Kumar; John A Thompson; Mark Castillas
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

View more
  104 in total

Review 1.  Endogenous migration modulators as parent compounds for the development of novel cardiovascular and anti-inflammatory drugs.

Authors:  Wolfgang Poller; Madlen Rother; Carsten Skurk; Carmen Scheibenbogen
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

Review 2.  Engineered antibody therapies to counteract mutant huntingtin and related toxic intracellular proteins.

Authors:  David C Butler; Julie A McLear; Anne Messer
Journal:  Prog Neurobiol       Date:  2011-11-18       Impact factor: 11.685

3.  Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice.

Authors:  Hua Li; Steven Tuyishime; Te-Lang Wu; Wynetta Giles-Davis; Dongming Zhou; Weidong Xiao; Katherine A High; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2010-12-14       Impact factor: 11.454

4.  Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 Å resolution.

Authors:  Thomas F Lerch; Jason K O'Donnell; Nancy L Meyer; Qing Xie; Kenneth A Taylor; Scott M Stagg; Michael S Chapman
Journal:  Structure       Date:  2012-06-21       Impact factor: 5.006

Review 5.  E Pluribus Unum: 50 Years of Research, Millions of Viruses, and One Goal--Tailored Acceleration of AAV Evolution.

Authors:  Dirk Grimm; Sergei Zolotukhin
Journal:  Mol Ther       Date:  2015-09-21       Impact factor: 11.454

Review 6.  Adeno-associated Virus as a Mammalian DNA Vector.

Authors:  Max Salganik; Matthew L Hirsch; Richard Jude Samulski
Journal:  Microbiol Spectr       Date:  2015-08

Review 7.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

8.  A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes.

Authors:  Zhenhua Yuan; Chunping Qiao; Peiqi Hu; Juan Li; Xiao Xiao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

9.  A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection.

Authors:  Lin Yang; Jiangang Jiang; Lauren M Drouin; Mavis Agbandje-McKenna; Chunlian Chen; Chunping Qiao; Dongqiuye Pu; Xiaoyun Hu; Da-Zhi Wang; Juan Li; Xiao Xiao
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

Review 10.  State-of-the-art human gene therapy: part I. Gene delivery technologies.

Authors:  Dan Wang; Guangping Gao
Journal:  Discov Med       Date:  2014 Jul-Aug       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.